Jubilant Biosys, a leading contract research and development organisation, has expanded its clinical research footprint by launching a new facility in Noida. The additional centre is equipped with modern laboratories, cutting edge instruments, and expanded research teams to support early and mid stage drug discovery programmes.

The expansion reflects growing demand for integrated research services that can accelerate the translation of scientific insights into therapeutic candidates. Jubilant Biosys’ Noida facility will focus on bridging preclinical biology, medicinal chemistry, pharmacology and translational science, enabling faster evaluation of drug targets and candidate optimisation.

According to company leadership, the new centre will enhance collaboration with global pharma and biotech partners by offering scalable research capacity and shared expertise across scientific domains. The expanded infrastructure aims to support intensive screening, in vitro and in vivo studies, biomarker profiling, and data driven decision making throughout the discovery pipeline.

The investment in Noida underscores a broader trend in which research services organisations are building comprehensive platforms that reduce cycle times and cost for drug discovery projects. Jubilant Biosys officials believe that this expansion will help strengthen its position as a trusted partner for clients seeking end-to-end discovery support from early hypothesis testing to translational research readiness.

The facility also supports capacity building for young scientists and research professionals, offering opportunities for training and development in advanced experimental platforms. With this expansion, Jubilant Biosys continues to reinforce its commitment to scientific excellence and operational scale in the competitive global research services market.